Alpaslan Tasdogan

机构：German Cancer Research Center, Universität Ulm, Heidelberg University, University Hospital Heidelberg, National Center for Tumor Diseases, Children's Medical Center, Essen University Hospital, Leibniz Institute for Analytical Sciences - ISAS, Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie, Klinik und Poliklinik für Neurologie, University Hospital Ulm, West German Heart and Vascular Center Essen, Technische Hochschule Ulm, Deutsches Konsortium für Translationale Krebsforschung, Stiftung Universitätsmedizin Essen, University of Duisburg-Essen · ORCID：0000-0003-2543-852X

发表论文 238 篇 · 总被引 4729 次 · h-index 32

代表论文

• Diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis: A meta-analysis (2026 · European Journal of Cancer · 被引 2)
• l-2-Hydroxyglutarate impairs neuronal differentiation through epigenetic activation of MYC expression (2026 · Journal of Clinical Investigation · 被引 2)
• Autophagy maintains high endothelial venule identity and function during inflammation (2026 · Immunity · 被引 1)
• S1 guideline sweat gland carcinoma (2026 · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 被引 1)
• Reverse engineering of BNIP3 identifies a mitochondrial protective peptide (2026 · Nature Communications · 被引 1)
• Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations (2026 · British Journal of Pharmacology · 被引 1)